May 7 |
Aligos Therapeutics Reports Recent Business Progress andĀ First Quarter 2024 Financial Results
|
Apr 30 |
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
|
Apr 25 |
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
|
Apr 25 |
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
|
Apr 9 |
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
|
Apr 3 |
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
|
Mar 27 |
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
|
Mar 27 |
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
|
Mar 18 |
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
|
Mar 14 |
Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|